Compare ING Groep NV (ING) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Recursion Pharmaceuticals Inc — how do they compare? ING Groep NV trades at $33.37 (market cap $93.76B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: ING Groep NV is far larger — about 43.8× Recursion Pharmaceuticals Inc's market cap, and ING Groep NV pays a 3.95% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| ING | RXRX | |
|---|---|---|
Market Cap | $93.76B | $2.14B |
Volume | 4,620,220 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $37.27 | $6.79 |
52-Week Low | $23.66 | $2.84 |
Typical Hold Time | 94 Days | 23 Days |
Enterprise Value | $236.48B | $1.66B |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.43, down 1.44% today, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 results with revenue growth and raised 2027 ROE targets above 16%. Valuation metrics show a P/E of 12.86 and P/B of 1.68, while analyst consensus remains strongly positive with 64.7% buy ratings.
ING presents a compelling investment case with solid profitability (28.3% net margin) and consistent earnings outperformance, though negative cash flow trends and regulatory challenges in Australia warrant caution. The stock's current technical weakness may offer entry opportunities for long-term investors attracted by the company's growth trajectory and dividend yield.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
